Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Galanello, Renzo and Piga, Antonio and Forni, Gian Luca and Bertrand, Yves and Foschini, Maria Loreta and Bordone, Elena and Leoni, Giovanbattista and Lavagetto, Antonella and Zappu, Antonietta and Longo, Filomena and Maseruka, Henry and Hewson, Nicola and Sechaud, Romain and Belleli, Rossella and Alberti, Daniele (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 91 (10). pp. 1343-1351. ISSN 1592-8721

Abstract

Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. This study evaluated the safety and tolerability of deferasirox in pediatric patients with transfusion-dependent beta-thalassemia major. Efficacy and pharmacokinetic assessments were secondary objectives.

Item Type: Article
Related URLs:
Related URLs:
Date Deposited: 05 Oct 2012 23:45
Last Modified: 05 Oct 2012 23:45
URI: https://oak.novartis.com/id/eprint/8695

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.